Trial · NCT06923280

Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens

NCT06923280, Not applicable, Recruiting, Huashan Hospital

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens. Trials, record NCT06923280. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06923280

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens
NCT number: NCT06923280
Status: Recruiting
Phases: Not applicable
Enrollment: 72 participants, estimated
Lead sponsor: Huashan Hospital
Conditions: Hepatitis B, Chronic
Interventions: Pegylated Interferon-alpha (IFN)
First posted: 2025-04-11
Last updated: 2026-07-29

Source ClinicalTrials.gov

Registered outcomes23

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	HBV DNA and HBsAg undetectable with/without anti-HBs	week 72	Proportion of patients achieving HBV DNA below the lower limit of quantification (LLOQ; \<20 IU/mL), HBsAg undetectable (\<0.05 IU/mL) (with or without anti-HBs seroconversion), and normal liver biochemical indices at Week 72.
Secondary	HBV DNA and HBsAg undetectable with/without anti-HBs during the study	Weeks 24, 48, and 96	Proportion of patients achieving HBV DNA \<20 IU/mL, HBsAg \<0.05 IU/mL (with or without anti-HBs), and normal liver biochemistry at Weeks 24, 48, and 96.
Secondary	HBV DNA and HBsAg undetectable during the study	Weeks 24, 48, 72, and 96	Proportion of patients achieving HBsAg \<0.05 IU/mL and HBV DNA \<20 IU/mL at Weeks 24, 48, 72, and 96.
Secondary	HBsAg level	Weeks 24, 48, 72, and 96	HBsAg levels in each group at Weeks 24, 48, 72, and 96
Secondary	HBsAg decline from baseline	Weeks 24, 48, 72, and 96	Magnitude of HBsAg decline from baseline in each group at Weeks 24, 48, 72, and 96
Secondary	HBsAg seroclearance	Weeks 24, 48, 72, and 96	HBsAg seroclearance rate (HBsAg \<0.05 IU/mL) in each group at Weeks 24, 48, 72, and 96
Secondary	HBsAg seroconversion	Weeks 24, 48, 72, and 96	HBsAg seroconversion rate (anti-HBs ≥10 mIU/mL) in each group at Weeks 24, 48, 72, and 96
Secondary	HBeAg seroclearance	Weeks 24, 48, 72, and 96	HBeAg seroclearance rate in baseline HBeAg-positive patients at Weeks 24, 48, 72, and 96
Secondary	HBeAg seroconversion	Weeks 24, 48, 72, and 96	HBeAg seroconversion rate (anti-HBe positivity) in baseline HBeAg-positive patients at Weeks 24, 48, 72, and 96
Secondary	HBV DNA level	Weeks 24, 48, 72, and 96	HBV DNA levels in each group at Weeks 24, 48, 72, and 96

1 to 10 of 23Source ClinicalTrials.gov

See all 23 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers6

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
24915612	BACKGROUND	PubMed
36346079	BACKGROUND	PubMed
39214467	BACKGROUND	PubMed
39266050	BACKGROUND	PubMed
39389081	BACKGROUND	PubMed
42176181	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06923280

GET https://conductscience.org/api/trials/v1/NCT06923280/registered?page=2

API reference For AI assistants